Bariatric surgery can reduce the risk of melanoma

Share This Post

In addition to rapid and lasting weight loss and other health benefits, bariatric surgery is now associated with a 61% reduced risk of malignant melanoma, which is the deadliest skin cancer most closely associated with excessive sun exposure.

The new study will be released on Thursday at the European Obesity Conference in Vienna, Austria. The study also found that the risk of skin cancer in people undergoing bariatric surgery generally decreased by 42%. Among a group of 2,007 obese participants undergoing bariatric surgery in Sweden, the median follow-up period was 18 years.

In this study, subjects who chose surgery as an obesity treatment were compared with 2,040 obese Swedes. The control group had similar basic conditions as the surgical patients, including age, gender, height, cardiovascular risk factors, and psychological Social variables and personality traits, but no cuts.

A research team led by Magdalena Taube from the University of Gothenburg in Sweden believes that changing the risk of melanoma in subjects is deep weight loss. This finding supports the notion that obesity is a risk factor for melanoma, and shows that weight loss in obese patients can reduce the risk of increasing fatal cancer in many countries for decades.

The American Cancer Society estimates that in 2018, about 91,270 new melanomas will be diagnosed in the United States, with 55,150 males and 36,120 females. About 9,320 people will die from the disease. The organization also reported a recent increase in the incidence of melanoma: between 2008 and 2018, the number of new melanoma cases diagnosed each year increased by 53%.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy